Skip to content
Subscriber Only

Carlyle-Backed China Biotech Firm Plans Hong Kong IPO

  • Abbisko could raise about $250 million in an IPO this year
  • Company raised $123 million in series D funding round
 Abbisko joins a growing wave of health-care and biotech firms listing in Hong Kong after a record year for share sales in the sector.

 Abbisko joins a growing wave of health-care and biotech firms listing in Hong Kong after a record year for share sales in the sector.

Photographer: Lam Yik/Bloomberg

Abbisko Therapeutics Co., an oncology-focused Chinese biotech company, is planning a Hong Kong initial public offering that could raise about $250 million, according to people familiar with the matter.

Abbisko, which is backed by investors including Carlyle Group Inc. and Warburg Pincus, is working with advisers on the offering, the people said. The company aims to list as soon as this year, they said, asking not to be identified as the information isn’t public.